Tamoxifen

Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells[1][2][3]. Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively[5]. Tamoxifen activates autophagy and induces apoptosis[4]. Tamoxifen can also be dissolved in corn oil (HY-Y1888) for use in inducing gene knockout in CreER transgenic mice. (Note: The solution should be prepared protected from light, freshly made before use, and storage is not recommended.) . Tamoxifen has better solubility in corn oil compared to Tamoxifen Citrate (HY-13757) [6].

Product Specifications

CAS Number

[10540-29-1]

Product Name Alternative

ICI 47699; (Z) -Tamoxifen; trans-Tamoxifen

UNSPSC

12352005

Hazard Statement

H302, H350, H360, H410

Target

Apoptosis; Autophagy; Estrogen Receptor/ERR; HSP

Type

Reference compound

Related Pathways

Apoptosis; Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Cancer; Endocrinology

Assay Protocol

https://www.medchemexpress.com/Tamoxifen.html

Purity

99.96

Solubility

DMSO : 13.46 mg/mL (ultrasonic) |Ethanol : 50 mg/mL (ultrasonic)

Smiles

CC/C(C1=CC=CC=C1)=C(C2=CC=CC=C2)/C3=CC=C(C=C3)OCCN(C)C

Molecular Formula

C26H29NO

Molecular Weight

371.51

Precautions

H302, H350, H360, H410

References & Citations

[1]Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998 Nov 26;339 (22) :1609-18.|[2]Hawariah A, et al. In vitro response of human breast cancer cell lines to the growth-inhibitory effects of styrylpyrone derivative (SPD) and assessment of its antiestrogenicity. Anticancer Res. 1998 Nov-Dec;18 (6A) :4383-6.|[3]Jun Nagai, et al. Hyperactivity with Disrupted Attention by Activation of an Astrocyte Synaptogenic Cue. Cell. 2019 May 16;177 (5) :1280-1292.e20.|[4]Zhao R, et al. Tamoxifen enhances the Hsp90 molecular chaperone ATPase activity. PLoS One. 2010 Apr 1;5 (4) :e9934.|[5]Kedjouar B, et al. Molecular characterization of the microsomal tamoxifen binding site. J Biol Chem. 2004 Aug 6;279 (32) :34048-61.|[6]Laura Cooper, et al. Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors. J Med Chem. 2020 Sep 4.|[7]Feil S, et, al. Inducible Cre mice. Methods Mol Biol. 2009;530:343-63.|[8]Bi Q, et al. Microglia-derived PDGFB promotes neuronal potassium currents to suppress basal sympathetic tonicity and limit hypertension. Immunity. 2022 Aug 9;55 (8) :1466-1482.e9.|[9]Chen MY, et al. A review of tamoxifen administration regimen optimization for Cre/loxp system in mouse bone study. Biomed Pharmacother. 2023 Sep;165:115045.|[10]El-Beshbishy HA. Hepatoprotective effect of green tea (Camellia sinensis) extract against tamoxifen-induced liver injury in rats. J Biochem Mol Biol. 2005 Sep 30;38 (5) :563-70. |[11]El-Beshbishy H A. The effect of dimethyl dimethoxy biphenyl dicarboxylate (DDB) against tamoxifen-induced liver injury in rats: DDB use is curative or protective[J]. BMB Reports, 2005, 38 (3) : 300-306.|[12]Kim CS, et al. Effects of silybinin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen in rats. Anticancer Res. 2010 Jan;30 (1) :79-85.|[13]Reid JM, et al. Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studies. Cancer Chemother Pharmacol. 2014 Dec;74 (6) :1271-8.